6. Литература

Поставить закладку

• Alexanian R., Dimopoulos M.A., Delasale K., Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887890.
• Avet-Loiseau H., Leleu X.,Rosel M., et al. Bortezomib plus dexamethasone induction improves outcome in patients with t(4;14) myeloma but not outcome of patients with del (17p). J.Clin.Oncol. 2010;28:(30):4630-4634.
• Barlogie B., Attal M., et al. Long-term follow-up of autotransplantation trails for multiple myeloma: update of protocols conducted by the intergroup francophone du myelome, southwest oncology group, and university of Arkansas for medical sciences. J Clin Oncol 2010;28,1209-1214.
• Bringhen S., Larocca, Rossi D., et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116: 4745-4753.
• Dadacaridou M., Papanicolaou X., Maltesas D., et al/ Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple Myeloma. J BUON 2007;12: 41-44.
• Damaj G., Malard F., Hulin C. Efficacy of Bendamustine in Relapsed/refractory Myeloma Patients: Results from the French Compassionate Use Program. Haematologica 2011;96 (suppl.)1:abstr.140.
• Davies F.E., Wu P., Jenner M., et al. The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica 2007; 92(8): 1149-1150.
• Dimopolous M., Chen C., Spencer A., Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma, Leukemia, 2009, 23, 2147-52
• Dimopoulos M., Kyle R., Fermand J-P., et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117(18): 4701-4705.
• Dimopoulos M.A., Palumbo A., Attal M., et al. Optimization the use of lenalidomide in relapse or refractory multiple Myeloma: consensus statement/ Leukemia 2011: 1012.
• Dimopoulos M.A., Spencer A., Attal M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple Myeloma. N.Engl.J.Med. 2007; 357:2123-2132.
• Durie B.G.M., Harousseau J-L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20 (9): 14671473. 9a. Rajkumar S.V., Harousseau J.-L., Anderson K.C. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117(18):4691-5
• Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma: Correlation of measure Myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36 (9): 842-854.
• Einsele H., Liebisch P., et al. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial), Blood, 2009;114, abstr 131.
• Greipp P.R., San Miguel J.F., Durie B.G., et al. International Staging System for Multiple Myeloma. J.Clin Oncol. 2005; 23 (15): 3412- 3420.
• Harousseau J.-L., Dreyling M. Multiple Myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (suppl.5): 155-157.
• Hoskin P.J., Yarnold J.R., Roos D.R. Consensus Statement: Radiotherapy and bone metastases (Second Consensus Workshop in Palliative Radiotherapy and Symptom Control. London, 2000). J.Clin. Oncol. 2001;13 :88-90.
• Hrusovsky I., Emmerich B., Rohr A., et al. Bortezomib Retreatment in Relapsed Multiple Myeloma - Results from a Retrospective Multicentre Survey in Germany and Switzerland. Oncology 2010; 79 (3-4): 247-254.
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of International Myeloma Working Group. Br. J. Haematol. 2003; 121 (5): 749-757.
• Jagannath S., Durie BGM, Lee Wolf J., et al/ Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for frontline treatment of multiple Myeloma. Br. J. Haematol. 2009; 359: 906-917.
• Jagannath S., Richardson P.G., Barlogie B. et al. Bortezomib in combination with dexamethasone for the tretment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica/the hematology journal 2006; 91(7): 929-934.
• Jemal A., Siegel R., Xu J., et al. Cancer Statistics, 2010. J. Clin Oncol. 2010; 60: 277-300.
• Knop S, Gerecke C, Liebisch P et al. Lenalidomide, Adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009;113(18):4137-4143
• Knop S., Straka C., Haen M., et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90(9):1287-1288.
• Kropff M., Bisping G., Schuck E., et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapse multiple myeloma. Br.J. Haematol. 2007; 138 (3): 330-337.
• Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23 (1): 3-9.
• Kyle R.A., Rajkumar SV: Multiple myeloma. N. Engl. J. Med. 2004; 351: 1860-1873.
• Larocca A., Oliva S., Offinady M, et al. Subcutaneous Velcade Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) In Frail, Elderly, Newly Diagnosed Multiple Myeloma Patients: A Phase II Community-Based Study. Haematologica 2013; 98(Suppl.1):477 (Abstract S 1154).
• Rosinol L., Cibeira M.T., Uniburu C. et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur. J. Haematol. 2006;76(5):405-408.
• Lenhard R.E., Oken M.M., Barnes J.M., et al. High-dose cyclophosphamide. An effective treatment for avanced refractory multiple myeloma. Cancer 1984;53(7): 1456-1460.
• Lentzsch S, O’Sullivan A, Kennedy R et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with refractory or relapsed multiple myeloma is safe and highly effective: results of phase I/II open-label, dose escalation study [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):304
• Ludwig H, .Avet-Loiseau H., Blade J.et al. - European perspective on multiple myeloma treatment strategies: update following recent congresses. The Oncologist, 2012; 17: 592-606.
• Ludwig H., Durie B., McCarthy Ph. et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood, 2012, 119; 3003-3015.
• Ludwig H., Kasparu H., Griel R., et al. Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated. Blood 2012 120: Abstract 943.
• Mateos M.-V, Richardson P., Schlag R., Khuageva N.K. et al.; Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial, JCO, 2010, 1-13
• Mateos M.-V., Oriol A., Gutierrez N., et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial Lancet Oncol. 2010 Oct;11(10):934-41.
• Mateos M.-V., San Miguel J. How should we treat newly diagnosed multiple myeloma patients? ASH Education Book 2013, 2013 (1): 488495.
• Mateos M.-V, Oriol A., Martinez-Lopez J., et al. Bortezomib, melphalan and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomized trial. Lancet Oncol. 2010; 11 (10):934-941.
• McCarthy P.L., Owzar K., Hofmeister C., et al. Lenalidomide after stem cell transplantation for multiple myeloma. NEJM, 2012; 366, 1770-81
• McCarthy PL., Owzar K., Anderson KC. Et al. Phase III intergroup study of Lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 BMT-CTN 100104. Haematologica 2011;96 (1s):S23.
• Moreau P., Pylypenko H., Grosicki S. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study. Lancet Oncol 2011;12(5):431-40.
• Moreau P., San Miguel J., Ludwig H., et al. Multiple myeloma; ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann.Oncol. 2013, 24 [suppl. 6]:133-137.
• Morgan G, Child J, Gregory W, et al. - Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcome from a randomized controlled trial. Lancet Oncology, 2011, 12 (8): 743-752.
• Munshi N.C., Anderson K.C., Bergsagel L. et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011; 117 (18): 4696-4700.
• Myeloma: Biology and management. Second Edition / Ed. Malpas J.S., Bergsagel D.E., Kyle R.A., Anderson C.A. - Oxford, New York, Tokyo. Oxford University Press, 1998.
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^TM) Multiple Myeloma Version 2.2014 NCCN.org
• Niesvizky R., Flinn I.W.,Rifkin R.M., et al. Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple Myeloma patients [abstract]. Blood 2010; 116: 619.
• Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. J. Clin. Oncol. 2007; 25(25): 3892-3901.
• Palumbo A., Bringhen S., Rossi D., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J.Clin. Oncol. 2010; 28 (34): 5101-5109.
• Palumbo A., Bringhen S., Zweegman S. et al. Secondary Malignancies in Elderly Myeloma Patients. Haematologica 2011; 96 suppl.1: 24.
• Palumbo A., Hajek R., Delforge M., et al. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma, N Engl J Med, 2012, 19, 1759-1769
• Palumbo A., Magarotto V. Novel treatment paradigm for elderly patients with multiple myeloma. Am. J. Blood Res. 2011; 1(2): 190-204.
• Petrucci M.T., Giraldo P., Corradini P., et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br.J. Haematol.2013; 160(5):649-659.
• Ponisch W., Mitrou P.S., Mercle K. et al. East German Study Group of Hematology and Oncology (OSH). Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to the treatment with melphalan and prednisone - a randomized phase III study of East German Study Group of Hematology and Oncology (OSH). J. Cancer Res. Clin. Oncol. 2006; 132: 205-212.
• Rajkumar S.V., Jacobus S., Callanderr N.S., et al. Lenalidomide plus high-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol.2010; 11 (1):29-37.
• Reece DE, Masih-Khan E, Khan A et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (Revlimid®) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma [abstract] Blood (ASH Annual Meeting Abstracts). 2010;116(21):3055
• Richardson P., Weller E., et al. Lenalidomide, bortezomib and dexamethasone combination therapy in dexamethasone in patients with newly diagnosed multiple myeloma. Blood, 2010;116:679-686.
• Richardson P.G., Barlogie B., Berenson J. et al. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. N. Engl. J. Med. 2003; 348 (26): 2609-2617.
• Richardson P.G., Delforge M., Beksac M., et al. Management of treatment-emergent neuropathy in multiple Myeloma. Leukemia 2011: 113.
• Richardson P.G., Jagannath S., Jakubowiak A.J, et al. Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up. Blood Blood (ASH Annual Meeting Abstracts). 2010;1169210:3049.
• Richardson P.G., Sonnefeld P., Schuster M. et al. . Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110 (11): 3557-3560.
• Rodon Ph., Hulin C., Pegourie Br., et al. Bendamustine, Bortezomib and Dexamethasone (BVD) In Elderly Patients With Multiple Myeloma In First Relapse: Final Analysis Of The Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial. Blood (ASH 2013 Annual Meeting Abstract) 2013;122 (21):1971
• San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N.Engl. J. Med. 2008; 359 (9): 906-917.
• San-Miguel J. F., Dimopoulos M.A., Stadtmauer E.A., Rajkumar S. V., Siegel D., Bravo M.-L., Olesnyckyj M., R.D. Knight, J.B. Zeldis, J.-L. Harousseau, D.M. Weber. Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone. Clin Lymphoma Myeloma Leukemia 2010; 120:1-6.
• San-Miguel J., Harousseau J.-L., Joshua D., et al. Individualizing Treatment of Patients with Myeloma in the Era of Novel Agents. J. CLin. Oncol. 2008; 26 (16):2761-2766.
• Schey SA, Morgan GJ, Ramasamy K et al. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol. 2010;150(3):326-333
• Sonneveld P., Longen J.L.M. Dealing with Neuropathy in Plasma-Cell Dyscrasias. American Society of Hematology Education Program Book 2010: 423-430.
• Sonneveld P., Schmidt-Wolf I., et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma. Blood, 2010;116, abstr 40.
• Stadtmauer E., Weber D., Niesvizky R., et al. Lenalidomide with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur.J.Haematology 2009; 82 (6):426-432.
• Treatment of Multiple Myeloma and Relation Disorders Ed. S. V. Rajkumar and R.A. Kyle. Cambridge University Press, 2009.
• van de Donk NW, Gorgun G, Groen RW et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Management and Research 21012;4:253-268
• Vickrey E., Allen S., Mehta J. and Signal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple Myeloma patients receiving bortezomib therapy. Cancer 2009; 115: 229-232.
• Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple Myeloma in North America. N. Engl. J.Med. 2007; 357: 2133-2142.
• Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и соавт. Частота, характеристика и методы лечения периферической нейропатии у больных множественной миеломой, получавших бортезомиб (велкейд). Онкогематология 2008; 3: 52-62.
• Вотякова О.М. Множественная миелома. В кн. «Руководство по химиотерапии опухолевых заболеваний» под ред. Н.И.Переводчиковой. 3-е изд., доп. пер.- М.:Практическая медицина, 2011, стр.362-372.
• Вотякова О.М., Османов Д.Ш., Демина Е.А. Использование велкейда при множественной миеломе. Тер.Архив. 2007; 79 (7): 70-73.
• Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований России и странах СНГ 2007 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009; 20 (3)(приложение 1):1-156.
• Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). Под редакцией В.И. Чиссова, В.В. Старинского, Г.В. Петровой. - Москва: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. 2013.-289 с.
• Менделеева Л.П. Современное лечение множественной миеломы, Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009; 2 (1): 64-65.
• Покровская О.С., Менделеева Л.П., Урнова Е.С., и др. Влияние бортезомиба на эффективность мобилизации гемопоэтических стволовых клеток крови у больных множественной миеломой. Тер. Архив. 2012;84(7): 35-41.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница